Oncogene genomic locus

Oncogene genomic loci refer to the specific chromosomal positions of genes that, when altered by mutations, amplifications, or translocations, drive the development and progression of cancer [1]. These loci typically house proto-oncogenes, which are essential for normal cellular functions such as growth and signal transduction but become oncogenic through gain-of-function modifications [2]. In clinical oncology, these loci serve as critical diagnostic and prognostic biomarkers; for instance, the amplification of the ERBB2 locus or the translocation of BCR-ABL1 defines specific therapeutic cohorts [3]. While traditional targeted therapies primarily inhibit the protein products encoded by these loci, such as tyrosine kinases, emerging modalities like CRISPR-Cas9 and antisense oligonucleotides aim to target the genomic DNA or primary transcripts directly [4]. The study of these loci is central to the concept of oncogene addiction, where cancer cells become dependent on a single activated oncogenic pathway for survival [2]. However, therapeutic intervention at these loci faces significant challenges, including the rapid emergence of resistance through secondary mutations and the risk of off-target effects in the genome [5].

Other names

Oncogene genomic lociProto-oncogeneCancer-promoting geneOncogenic locusDriver gene locus

Inhibition of oncoprotein activity, gene silencing via antisense oligonucleotides, and direct genomic modification through gene editing technologies.